Unravelling Cancer's Blueprint
A New Era of Targeted Therapy – Precision oncology advancing first-in-class therapeutics for patients with high-risk cancers.
Pioneering Precision Oncology
We are dedicated to developing next-generation cancer therapeutics by targeting cancer's core vulnerabilities.
Born from Urgency
At Coiled, we're building a new paradigm for precision medicine. Our journey began with the conviction that the next wave of therapeutic breakthroughs lies in precisely targeting historically intractable proteins, particularly coiled-coil and other structurally complex oncogenic targets.
Spun out from A2A Pharmaceuticals, Inc. in 2025, Coiled is a focused, clinical-stage oncology company advancing promising new therapies for cancer. Following the reverse takeover of Roquefort Therapeutics, we are now listed on the London Stock Exchange AIM market.
Learn more about us